Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (71-80 of 230) with videos related to

Pageof 23
Sort By:
BJU International|December 24, 2010
Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy schemeGuillaume Ploussard, Evanguelos Xylinas, Xavier Durand, et al.
The Journal of Urology|August 18, 2009
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigenGuillaume Ploussard, Francis Dubosq, Véronique Boublil, et al.
BJU International|March 5, 2013
Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trialGuillaume Ploussard, Nathalie Nicolaiew, Charles Marchand, et al.
World Journal of Urology|April 18, 2009
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillanceGuillaume Ploussard, Gwendoline Plennevaux, Yves Allory, et al.
BJU International|November 26, 2009
Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancerGuillaume Ploussard, Laurent Salomon, Yves Allory, et al.
BJU International|September 16, 2010
Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammationAurelien Descazeaud, Nicolas Weinbreck, Grégoire Robert, et al.
World Journal of Urology|January 22, 2014
Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomyGuillaume Ploussard, Sarah J Drouin, Julie Rode, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
BJU International|February 16, 2011
Mid-term oncological control after laparoscopic radical cystectomy in men: a single-centre experienceNorman Gillion, Evanguelos Xylinas, Xavier Durand, et al.
Urology|October 5, 2010
Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature reviewEvanguelos Xylinas, Guillaume Ploussard, Xavier Durand, et al.
Pageof 23

Showing results (71-80 of 230) with videos related to

Sort By:
Pageof 23
BJU International|December 24, 2010
Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy schemeGuillaume Ploussard, Evanguelos Xylinas, Xavier Durand, et al.
The Journal of Urology|August 18, 2009
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigenGuillaume Ploussard, Francis Dubosq, Véronique Boublil, et al.
BJU International|March 5, 2013
Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trialGuillaume Ploussard, Nathalie Nicolaiew, Charles Marchand, et al.
World Journal of Urology|April 18, 2009
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillanceGuillaume Ploussard, Gwendoline Plennevaux, Yves Allory, et al.
BJU International|November 26, 2009
Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancerGuillaume Ploussard, Laurent Salomon, Yves Allory, et al.
BJU International|September 16, 2010
Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammationAurelien Descazeaud, Nicolas Weinbreck, Grégoire Robert, et al.
World Journal of Urology|January 22, 2014
Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomyGuillaume Ploussard, Sarah J Drouin, Julie Rode, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
BJU International|February 16, 2011
Mid-term oncological control after laparoscopic radical cystectomy in men: a single-centre experienceNorman Gillion, Evanguelos Xylinas, Xavier Durand, et al.
Urology|October 5, 2010
Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature reviewEvanguelos Xylinas, Guillaume Ploussard, Xavier Durand, et al.
Pageof 23